Table 2.
Patient baseline demographics and clinical characteristics in those who did/did not meet the three-component definition of clinical remission following 1 year of mepolizumab treatment.
| Three-component clinical remission definition† | ||
|---|---|---|
| Patients who achieved clinical remission (n=96) | Patients who did not achieve clinical remission (n=164) | |
| Age, mean (SD), years | 56.9 (10.30) | 57.0 (14.07) |
| Age at asthma diagnosis, mean (SD), years | n=96; 32.2 (16.52) | n=155; 35.5 (18.85) |
| Female, n (%) | 70 (73) | 120 (73) |
| Ethnicity, n (%) | ||
| Caucasian | 88 (92) | 147 (90) |
| Hispanic | 8 (8) | 13 (8) |
| African | 0 | 3 (2) |
| Other | 0 | 1 (<1) |
| BMI, mean (SD), kg/m2 | n=95; 28.0 (5.03) | n=164; 28.6 (5.69) |
| BMI category, n (%), kg/m2 | n=95 | n=164 |
| <18.5 | 0 | 1 (<1) |
| 18.5–<25.0 | 31 (33) | 41 (25) |
| 25.0–<30.0 | 33 (35) | 69 (42) |
| 30.0–<35.0 | 23 (24) | 35 (21) |
| ≥35.0 | 8 (8) | 18 (11) |
| Smoking status, n (%) | ||
| Never | 63 (66) | 100 (61) |
| Ex-smoker (>6 months) | 31 (32) | 54 (33) |
| Current smoker | 0 | 2 |
| Passive smoker | 1 (1) | 5 (3) |
| Not available | 1 (1) | 3 (2) |
| Exacerbations in the 12 months pre-mepolizumab treatment, mean (SD) | 4.1 (3.34) | 4.9 (3.61) |
| Baseline blood eosinophil count, † geometric mean (SD log), cells/µL | 675.94 (0.693) | 433.24 (1.521) |
| Baseline blood eosinophil count category,† n (%), cells/µL | ||
| <150 | 3 (3) | 13 (8) |
| 150–<300 | 7 (7) | 13 (8) |
| 300–<500 | 15 (16) | 48 (29) |
| 500–<700 | 21 (22) | 35 (21) |
| ≥700 | 50 (52) | 55 (34) |
| Allergic asthma, n (%) | 55 (57) | 103 (63) |
| Atopic sensitization, n (%) | n=96; 33 (34) | n=163; 75 (46) |
| Baseline ACT score, mean (SD) | n=90; 15.2 (5.04) | n=154; 13.6 (4.93) |
| Baseline ACT score category, n (%) | n=90 | n=154 |
| <20 (uncontrolled) | 72 (80) | 136 (88) |
| ≥20 (controlled) | 18 (20) | 18 (12) |
| Baseline post-bronchodilator FEV1%pred, mean (SD) | n=70 82.2 (23.29) |
n=102 73.6 (22.66) |
| OCS dependent in the 12 months pre-mepolizumab treatment, n (%) | 20 (21) | 85 (52) |
| Baseline OCS dose, median (IQR), mg/day | n=13; 5.0 (4.0, 13.3) | n=67; 10.0 (5.0, 20.0) |
| Previous omalizumab treatment, n (%) | n=96; 34 (35) | n=163; 71 (44) |
| Comorbidities, n (%) | ||
| Anxiety | 17 (18) | 34 (21) |
| Atopic dermatitis | 1 (1) | 1 (<1) |
| BronchiectasisP | 19 (20) | 33 (20) |
| Depression | 10 (10) | 37 (23) |
| EGPA | 2 (2) | 7 (4) |
| GERD | 15 (16) | 43 (26) |
| Hypersensitivity to NSAIDs | 18 (19) | 19 (12) |
| CRSwNP | 54 (56) | 67 (41) |
*Definition of clinical remission: exacerbation-free for 52 weeks, OCS-free at Week 52, and ACT score ≥20 at Week 52. 58 patients were excluded with missing ACT score at Week 52. †Where a blood eosinophil count of zero was recorded, a small value (i.e., minimum all non-missing results/2) was added prior to log transformation. ACT, asthma control test; BMI, body mass index; CRSwNP, chronic rhinosinusitis with nasal polyps; EGPA, eosinophilic granulomatosis with polyangiitis; FEV1, forced expiratory volume in 1 second; GERD, gastroesophageal reflux disease; IQR, interquartile range; NSAID, non-steroidal anti-inflammatory drug; OCS, oral corticosteroid; pred, predicted; SD, standard deviation.